<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alpelisib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alpelisib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alpelisib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="121400" href="/d/html/121400.html" rel="external">see "Alpelisib: Drug information"</a> and <a class="drug drug_patient" data-topicid="121486" href="/d/html/121486.html" rel="external">see "Alpelisib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53211859"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Piqray (200 MG Daily Dose);</li>
<li>Piqray (250 MG Daily Dose);</li>
<li>Piqray (300 MG Daily Dose);</li>
<li>Vijoice</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54730025"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Piqray (200 MG Daily Dose);</li>
<li>Piqray (250 MG Daily Dose);</li>
<li>Piqray (300 MG Daily Dose)</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56767122"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Phosphatidylinositol 3-Kinase Inhibitor</span>;</li>
<li>
<span class="list-set-name">Phosphatidylinositol 3-Kinase (PI3K) Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F56767138"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Alpelisib is available as 2 different brand names (Vijoice [only product FDA approved for use in pediatric patients] and Piqray); the indications and dosages differ between products.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dfeb4b47-68ec-4826-bf65-b5b109a226b3">PIK3CA-related overgrowth spectrum, severe manifestations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>PIK3CA-related overgrowth spectrum (PROS), severe manifestations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;6 years: Vijoice: Oral: 50 mg once daily; continue therapy until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;18 years: Vijoice: Oral: Initial: 50 mg once daily; after 6 months of treatment, consider increasing dose to 125 mg once daily to optimize clinical and/or radiologic response. Continue therapy until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Vijoice: Oral: 250 mg once daily; continue therapy until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIK3CA-related overgrowth spectrum (PROS), treatment:</b> Vijoice: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Recommended Alpelisib Dosage Reduction Levels<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left"></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Children ≥2 years and Adolescents &lt;18 years</p></th>
<th align="left">
<p style="text-indent:0em;">Adolescents ≥18 years</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a </sup>Only 1 dose reduction is permitted for pancreatitis.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Current dose</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">125 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">250 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">First dose reduction level</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;">If 50 mg dose is not tolerated, discontinue alpelisib.</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">125 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Second dose reduction level</p></td>
<td align="left">
<p style="text-indent:0em;">If further dose reductions are required, discontinue alpelisib.</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg once daily</p></td></tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;">If further dose reductions are required, discontinue alpelisib.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Alpelisib Dosage Reduction and Toxicity Management</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">
<b>Children ≥2 years and Adolescents &lt;18 years</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Adolescents ≥18 years</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>SCARs = severe cutaneous adverse reactions (eg, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms)</p>
<p style="text-indent:0em;">
<sup>b</sup> Metformin may be considered in patients ≥10 years of age.</p>
<p style="text-indent:0em;">
<sup>c</sup> In patients ≥18 years of age, consider medications such as metformin, SGLT2 inhibitors, or insulin sensitizers (eg, thiazolidinediones, dipeptidyl peptidase-4 inhibitors).</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Dermatologic toxicity: Rash and SCARs<sup>a</sup></b></p>
<p style="text-indent:0em;">
<b>Note: </b>Dermatology consultation is recommended for all grades. Antihistamine administration prior to rash onset may decrease the rash incidence/severity. Do not reinitiate alpelisib if SCAR has occurred during therapy with alpelisib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 1 (&lt;10% BSA with active skin toxicity)</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">No alpelisib dosage adjustment required. Initiate topical corticosteroid therapy; consider adding an oral antihistamine to manage symptoms. If active rash is not improved within 28 days of appropriate therapy, add a low-dose systemic corticosteroid. Permanently discontinue alpelisib if a SCAR is confirmed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 2 (10% to 30% BSA with active skin toxicity)</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">No alpelisib dosage adjustment required. Initiate or intensify topical corticosteroid therapy and oral antihistamine treatment; consider low-dose systemic corticosteroid treatment. If rash improves to ≤ grade 1 within 10 days, systemic corticosteroid may be discontinued. Permanently discontinue alpelisib if a SCAR is confirmed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3 (eg, severe rash not responsive to medical management; &gt;30% BSA with active skin toxicity)</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment; initiate or intensify topical/systemic corticosteroid therapy and oral antihistamine treatment. If the etiology is not a SCAR, once improved to ≤ grade 1, either resume alpelisib at 50 mg once daily while continuing oral antihistamine treatment, or permanently discontinue alpelisib. Permanently discontinue alpelisib if a SCAR is confirmed, if patient was receiving antihistamines at the time of rash onset and antihistamine dose cannot be increased, or if ≥ grade 3 rash recurs.</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment; initiate or intensify topical/systemic corticosteroid therapy and oral antihistamine treatment. If the etiology is not a SCAR, once improved to ≤ grade 1, resume alpelisib at the next lower dosage level. Permanently discontinue alpelisib if a SCAR is confirmed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4 (eg, severe bullous, blistering or exfoliating skin conditions; any % BSA associated with extensive superinfection, with IV antibiotics indicated; life-threatening consequences)</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Permanently discontinue alpelisib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>GI toxicity: Diarrhea or Colitis</b></p>
<p style="text-indent:0em;">
<b>Note:</b> Consider consultation with a clinician with experience in the treatment of GI conditions.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">No alpelisib dosage adjustment required; initiate appropriate medical therapy and monitor as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to ≤ grade 1, then resume at the same dose level. If ≥ grade 2 diarrhea/colitis recurs, interrupt alpelisib treatment until improvement to ≤ grade 1, then resume at 50 mg once daily. Initiate or intensify appropriate medical therapy and monitor as clinically indicated; for colitis, consider additional treatment with enteric-acting and/or systemic corticosteroids.</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to ≤ grade 1, then resume at the same dose level. If ≥ grade 2 diarrhea/colitis recurs, interrupt alpelisib treatment until improvement to ≤ grade 1, then resume at the next lower dose level. Initiate or intensify appropriate medical therapy and monitor as clinically indicated; for colitis, consider additional treatment with enteric-acting and/or systemic corticosteroids.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to ≤ grade 1, then either resume alpelisib at 50 mg once daily or permanently discontinue alpelisib. Initiate or intensify appropriate medical therapy and monitor as clinically indicated; for colitis, consider additional treatment with enteric-acting and/or systemic corticosteroids. If ≥ grade 3 diarrhea/colitis recurs, consider permanent discontinuation of alpelisib.</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to ≤ grade 1, then resume at the next lower dose level. Initiate or intensify appropriate medical therapy and monitor as clinically indicated; for colitis, consider additional treatment with enteric-acting and/or systemic corticosteroids.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Permanently discontinue alpelisib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Hyperglycemia:</b> Based on fasting plasma glucose/fasting blood glucose values.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 1 (fasting glucose &gt;ULN to 160 mg/dL)</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">No alpelisib dosage adjustment required; initiate or intensify antihyperglycemic therapy.<sup>b,c</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 2 (fasting glucose &gt;160 to 250 mg/dL)</p></td>
<td align="left">
<p style="text-indent:0em;">No alpelisib dosage adjustment required; initiate or intensify antihyperglycemic therapy.<sup>b</sup> If fasting glucose does not decrease to ≤160 mg/dL within 21 days with appropriate antihyperglycemic therapy, interrupt alpelisib dose until improvement to ≤ grade 1, then resume alpelisib at 50 mg once daily and continue to follow fasting glucose specific recommendations.</p></td>
<td align="left">
<p style="text-indent:0em;">No alpelisib dosage adjustment required; initiate or intensify antihyperglycemic therapy.<sup>c</sup> If fasting glucose does not decrease to ≤160 mg/dL within 21 days with appropriate antihyperglycemic therapy, interrupt alpelisib dose by 1 dose level and continue to follow fasting glucose specific recommendations.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3 (fasting glucose &gt;250 to 500 mg/dL)</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib therapy; initiate or intensify antihyperglycemic therapy<sup>b</sup> and consider additional antihyperglycemic medications for 1 to 2 days until hyperglycemia improves. Administer IV hydration and consider appropriate intervention for electrolyte/ketoacidosis/hyperosmolar disturbances. If fasting glucose decreases to ≤160 mg/dL within 3 to 5 days with appropriate antihyperglycemic therapy, resume alpelisib at 50 mg once daily. If fasting glucose does not decrease to ≤160 mg/dL within 3 to 5 days with appropriate antihyperglycemic therapy, consultation with a clinician with expertise in hyperglycemia management is recommended to determine if treatment with alpelisib can be resumed or should be permanently discontinued. Permanently discontinue alpelisib if fasting glucose does not decrease to ≤160 mg/dL within 21 days following appropriate antihyperglycemic therapy. If ≥ grade 3 hyperglycemia recurs, consider permanent discontinuation of alpelisib.</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib therapy; initiate or intensify antihyperglycemic therapy<sup>c</sup> and consider additional antihyperglycemic medications for 1 to 2 days until hyperglycemia improves. Administer IV hydration and consider appropriate intervention for electrolyte/ketoacidosis/hyperosmolar disturbances. If fasting glucose decreases to ≤160 mg/dL within 3 to 5 days with appropriate antihyperglycemic therapy, resume alpelisib with the dose reduced by 1 dose level. If fasting glucose does not decrease to ≤160 mg/dL within 3 to 5 days with appropriate antihyperglycemic therapy, consultation with a clinician with expertise in hyperglycemia management is recommended. Permanently discontinue alpelisib if fasting glucose does not decrease to ≤160 mg/dL within 21 days following appropriate antihyperglycemic therapy.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4 (fasting glucose &gt;500 mg/dL)</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Interrupt alpelisib therapy; initiate or intensify antihyperglycemic therapy.<sup>b,c</sup> Administer IV hydration and consider appropriate intervention for electrolyte/ketoacidosis/hyperosmolar disturbances. Recheck fasting glucose within 24 hours (and as clinically indicated). If fasting glucose decreases to ≤500 mg/dL, follow fasting glucose value specific recommendations for grade 3 hyperglycemia. Permanently discontinue alpelisib if fasting glucose is confirmed at &gt;500 mg/dL with recheck.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Hypersensitivity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Severe</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Permanently discontinue alpelisib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Pancreatitis</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to &lt; grade 2, then resume at 50 mg once daily. If toxicity recurs, permanently discontinue alpelisib.</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to &lt; grade 2, then resume at the next lower dose level. Only 1 dose reduction is permitted for pancreatitis. If toxicity recurs, permanently discontinue alpelisib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue alpelisib.</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to &lt; grade 2, then resume at the next lower dose level. Only 1 dose reduction is permitted for pancreatitis. If toxicity recurs, permanently discontinue alpelisib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Permanently discontinue alpelisib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Pneumonitis</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">New or worsening respiratory symptoms or suspected pneumonitis</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Immediately interrupt alpelisib treatment and evaluate for pneumonitis.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Confirmed</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Permanently discontinue alpelisib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Other toxicities</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 1 or 2</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">No alpelisib dosage adjustment required; initiate appropriate medical therapy and monitor as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to ≤ grade 1, then either resume at 50 mg once daily or permanently discontinue alpelisib. If adverse reaction recurs at ≥ grade 3, consider permanent discontinuation of alpelisib. Initiate or intensify appropriate medical therapy and monitor as clinically indicated. Consider consultation with a qualified clinician with specific expertise in the field of the concerned adverse reaction.</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt alpelisib treatment until improvement to ≤ grade 1, then resume at the next lower dose level. Initiate or intensify appropriate medical therapy and monitor as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Permanently discontinue alpelisib.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F56767233"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥2 years and Adolescents: Vijoice: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate kidney impairment: There are no dosage adjustments provided in the manufacturer's labeling. No clinically significant pharmacokinetic differences were predicted in adult pharmacokinetic models for patients with mild to moderate renal impairment (CrCl 30 to &lt;90 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe kidney impairment: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F56767234"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment at baseline:</i> Vijoice: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to severe: Children ≥2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant differences in pharmacokinetics are expected, based on adult pharmacokinetic models.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i> Vijoice: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 2 total bilirubin elevation: <b>Note:</b> For dosage adjustment levels and other toxicity grades, follow dosage adjustment for "other toxicities" (See "Dosing: Pediatric").</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents &lt;18 years: Interrupt alpelisib treatment until improvement to ≤ grade 1; if resolved in ≤14 days, resume at the same dose level; if resolved in &gt;14 days, resume at 50 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: Interrupt alpelisib treatment until improvement to ≤ grade 1; if resolved in ≤14 days, resume at the same dose level; if resolved in &gt;14 days, resume at the next lower dose level.</p></div>
<div class="block doa drugH1Div" id="F53236763"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="121400" href="/d/html/121400.html" rel="external">see "Alpelisib: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Optimize blood glucose prior to initiating alpelisib. Alpelisib is available as 2 different brand names (Piqray and Vijoice); the indications and dosages differ between products. <b></b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e209e5b3-a38f-4feb-9792-5a9f077e6add">Breast cancer, advanced or metastatic, HR-positive, HER2-negative, PIK3CA-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced or metastatic, HR-positive, HER2-negative, PIK3CA-mutated:</b> Males and postmenopausal females: Piqray: <b>Oral:</b> 300 mg once daily (in combination with fulvestrant); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31091374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31091374'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12ecd54d-ac79-4604-bb53-75be9a9bae76">PIK3CA-related overgrowth spectrum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>PIK3CA-related overgrowth spectrum:</b> Vijoice:<b> Oral:</b> 250 mg once daily; continue until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> A missed dose may be administered (with food) within 9 hours after the usual administration time; if beyond 9 hours, skip the dose for that day and administer the dose for the next day at the usual time. If a dose is vomited, do not administer an additional dose on that day; resume the dosing schedule the next day at the usual time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53236765"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Kidney function estimated with the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;">Breast cancer: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">PIK3CA-related overgrowth spectrum: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant differences in alpelisib pharmacokinetics were noted based on CrCl 30 to &lt;90 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (effect on alpelisib pharmacokinetics is unknown).</p></div>
<div class="block doha drugH1Div" id="F53236766"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment at baseline: Child-Pugh classes A, B, or C: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant differences in pharmacokinetics are expected.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity during treatment: Grade 2 total bilirubin elevation: Interrupt alpelisib treatment until improvement to ≤ grade 1, then resume at the same dose level if resolved in ≤14 days or resume at the next lower dose level if improved in &gt;14 days. For dosage adjustment levels and other toxicity grades, follow dosage adjustment for “other toxicities” (see Dosing – Adjustment for Toxicity).</p></div>
<div class="block adr drugH1Div" id="F53265176"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced or metastatic</b></p>
<p style="text-indent:-2em;margin-left:2em;">Adverse reactions reported with concomitant fulvestrant in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (20%), pruritus (18%), skin rash (52%), xeroderma (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (14%), decreased serum calcium (27%), decreased serum glucose (26%), decreased serum magnesium (11%), decreased serum potassium (14%), hyperglycemia (65%; including severe hyperglycemia), increased gamma-glutamyl transferase (52%), weight loss (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (17%), decreased appetite (36%), diarrhea (58%; grade 3: 7%), dry mucous membranes (12%), dysgeusia (18%), dyspepsia (11%), increased serum lipase (42%), nausea (45%; grade 3: 3%), stomatitis (19% to 30%; grades 3: 2% to 3%), vomiting (27%; grade 3: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet count (14%; grades 3/4: 1%), lymphocytopenia (52%; grades 3/4: 8%), prolonged partial thromboplastin time (21%; grades 3: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (44%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (42%), headache (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (67%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (10%; including urinary tract infection with sepsis)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteonecrosis of the jaw (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ketoacidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Severe hypersensitivity reaction (grades 3/4)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIK3CA-Related Overgrowth Spectrum (PROS)</b></p>
<p style="text-indent:-2em;margin-left:2em;">Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin, decreased serum calcium (corrected), decreased serum magnesium, decreased serum phosphate, decreased serum potassium, decreased serum sodium, elevated glycosylated hemoglobin, hyperglycemia, increased gamma-glutamyl transferase, increased serum cholesterol, increased serum potassium, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Decreased hemoglobin, decreased neutrophils, decreased platelet count, leukopenia, lymphocytopenia, lymphocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cellulitis, eczema, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dry mucous membranes, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Soft tissue infection, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, memory impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, acneiform eruption, erythematous rash, maculopapular rash, papular rash, pruritic rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemic hyperosmolar syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, drug reaction with eosinophilia and systemic symptoms</p></div>
<div class="block coi drugH1Div" id="F53185632"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity to alpelisib or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F53236750"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms, have occurred with alpelisib. Inform patients of the signs/symptoms of SCARs (eg, prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, lymphadenopathy). Maculopapular rash (with or without pruritus and dry skin) is the most commonly occurring rash; rash generally develops within the initial 2 months of treatment (Nunnery 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Severe diarrhea and colitis may commonly occur with alpelisib; dehydration, acute kidney injury, and grade 3 diarrhea have been reported in patients with breast cancer. The median time to onset of grade 2 or 3 diarrhea was 46 days (range: 1 to 442 days). Some patients with PIK3CA-related overgrowth spectrum experienced grade 1 diarrhea. Antidiarrheal medication (eg, loperamide) was required to manage symptoms in a majority of patients with breast cancer who experienced diarrhea. Instruct patients with breast cancer to initiate antidiarrheal treatment, increase oral fluids, and notify their health care provider if diarrhea occurs during alpelisib treatment. Patients experiencing colitis may require additional treatment (eg, enteric-acting and/or systemic steroids).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia: Severe hyperglycemia, occasionally associated with hyperglycemic hyperosmolar state or ketoacidosis (some fatal), may occur with alpelisib. Hyperglycemia was reported in nearly two-thirds of patients with breast cancer. Grade 3 hyperglycemia occurred in one-third of those patients; grade 4 hyperglycemia and ketoacidosis (including fatal ketoacidosis cases) were reported in a small percentage of patients. Among patients who experienced grade 2 or higher hyperglycemia, the median time to first occurrence of hyperglycemia was 15 days (range: 5 to 517 days). Grade 1 or 2 hyperglycemia was reported in 12% of patients with PIK3CA-related overgrowth spectrum. Most hyperglycemia events in patients with breast cancer were managed with antihyperglycemic medication, with a majority utilizing metformin (either as single agent or in combination with other antihyperglycemic medications (eg, insulin, dipeptidyl peptidase-4 inhibitors, sulfonylureas). The median time from ≥ grade 2 hyperglycemia to at least 1 grade improvement was 8 days (range: 2 to 65 days). Most patients who continued fulvestrant but discontinued alpelisib (due to hyperglycemia) had fasting plasma glucose (FPG) levels that returned to baseline. Patients with type 1 or uncontrolled type 2 diabetes were excluded from clinical trials; the safety of alpelisib in these patients has not been established. Patients with a history of controlled type 2 diabetes were included in the breast cancer clinical trial but were not included in trials for patients with PIK3CA-related overgrowth spectrum (Nunnery 2019). Patients should be aware of signs/symptoms of hyperglycemia (eg, excessive thirst, frequent urination, increased urine volume, increased appetite with weight loss).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity reactions (including anaphylaxis, anaphylactic shock, and angioedema) have occurred with alpelisib. Manifestations of severe hypersensitivity reactions included dyspnea, flushing, rash, fever, or tachycardia. Grade 3 and 4 hypersensitivity reactions have occurred rarely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Severe pneumonitis, including acute interstitial pneumonitis and interstitial lung disease, may occur; pneumonitis was reported in a small percentage of patients with breast cancer. Patients should immediately report new or worsening respiratory symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Patients ≥65 years of age with breast cancer experienced a higher incidence of grades 3 and 4 hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• PIK3CA mutation status: Select patients for treatment of advanced/metastatic breast cancer based on the presence of one or more PIK3CA mutations in tumor tissue or plasma specimens; if no mutation is detected in a plasma specimen, test tumor tissue. Information on tests approved for detection of PIK3CA mutations in breast cancer is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc%2BkYYsON95PtA1EteUbfjUoJYJ%2BuveJw2PtFUTXMkK&amp;TOPIC_ID=138443" target="_blank">http://www.fda.gov/CompanionDiagnostics</a>.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F56767133"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Based on animal toxicity data, regular monitoring of growth and development is recommended in pediatric patients receiving alpelisib. In rats administered alpelisib at doses ~1.2 to 2.8 times human doses, growth plate thickening and decreased trabeculae of the knee joint, dentin thinning, and degenerative odontoblasts were observed. In a study of 39 pediatric patients receiving alpelisib for PIK3CA-related overgrowth spectrum, no new safety signals were observed; however, the data are insufficient to determine if alpelisib adversely impacts growth and development in humans.</p></div>
<div class="block foc drugH1Div" id="F53211860"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Piqray (200 MG Daily Dose): 200 mg (28 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Piqray (250 MG Daily Dose): 200 mg tablets and 50 mg tablets (28 ea, 56 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Piqray (300 MG Daily Dose): 2 x 150 mg (28 ea, 56 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vijoice: 50 mg (28 ea); 125 mg (28 ea); 200 mg tablets and 50 mg tablets (28 ea, 56 ea)</p></div>
<div class="block geq drugH1Div" id="F53211858"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53305093"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Piqray (200 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $944.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Piqray (250 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 &amp; 50 mg (per each): $472.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Piqray (300 MG Daily Dose) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 x 150 mg (per each): $472.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Vijoice Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1,392.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $1,392.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 &amp; 50 mg (per each): $696.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54730026"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Piqray (200 MG Daily Dose): 200 mg (28 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Piqray (250 MG Daily Dose): 200 mg tablets and 50 mg tablets (56 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Piqray (300 MG Daily Dose): 2 x 150 mg (56 ea)</p></div>
<div class="block admp drugH1Div" id="F56767235"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Vijoice: Administer with food at approximately the same time each day. Swallow intact tablet whole.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients unable to swallow tablet:</i> If patient is not able to swallow tablet, may prepare as an oral suspension. Place tablet in a glass containing 60 to 120 mL water and let stand for ~5 minutes. Crush tablets with a spoon and stir until oral suspension is obtained. Administer immediately after preparation; discard if not used within 60 minutes. After administration, add ~30 to 45 mL of water to same glass, stir with same spoon, and administer entire contents of glass. Repeat if any alpelisib particles remain. Do not prepare using any other liquids; only use water.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vomited dose:</i> If the patient vomits after taking the dose, do not administer an additional dose; resume dosing schedule on the following day at the usual time.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> A missed dose may be administered within 9 hours after the usual administration time. If &gt;9 hours have passed, skip that day's dose and administer the next day's dose at the usual time.</p></div>
<div class="block adm drugH1Div" id="F53236769"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food at approximately the same time each day. Swallow tablets whole (tablets should be intact prior to ingestion); do not chew, crush, or split.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Vijoice: </i>For patients unable to swallow tablets, may administer as an oral suspension (with food). Place tablets in a glass containing 60 to 120 mL of water (use water only) and let stand ~5 minutes, then crush tablets with a spoon and stir until a suspension forms. Administer suspension immediately after preparation (discard if not administered within 60 minutes). After administering the initial suspension, add another 30 to 45 mL of water to the same glass and stir to resuspend remaining particles and administer contents. Repeat if particles remain.</p></div>
<div class="block hazard drugH1Div" id="F53236753"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Alpelisib may cause teratogenicity and reproductive toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F53236754"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block usep drugH1Div" id="F56767128"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of severe manifestations of PIK3CA-related overgrowth spectrum (PROS) when systemic therapy is required (Vijoice: FDA approved in ages ≥2 years and adults); treatment of HR-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer in males or postmenopausal females, in combination with fulvestrant, following progression on or after an endocrine-based regimen (Piqray: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> PROS indication received accelerated approval based on response rate and duration of response; continued approval may be contingent upon confirmatory trials.</p></div>
<div class="block mst drugH1Div" id="F53236744"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Alpelisib may be confused with abemaciclib, acalabrutinib, afatinib, Alecensa, alectinib, avapritinib, axitinib, copanlisib, duvelisib, idelalisib.</p>
<p style="text-indent:-2em;margin-left:4em;">Alpelisib is available as 2 different brand names, Piqray and Vijoice. The indications and dosages differ between products.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53241222"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F53241219"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Inhibitors: May increase the serum concentration of Alpelisib. Management: Avoid coadministration of BCRP/ABCG2 inhibitors and alpelisib due to the potential for increased alpelisib concentrations and toxicities. If coadministration cannot be avoided, closely monitor for increased alpelisib adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Substrates (High risk with Inducers): Alpelisib may decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Alpelisib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F53236752"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Following a single alpelisib 300 mg dose, a high-fat and high-calorie meal (985 calories with 58.1 g of fat) increased the alpelisib AUC and C<sub>max</sub> by 73% and 84%, respectively; a low-fat and low-calorie meal (334 calories with 8.7 g of fat) increased the alpelisib AUC and C<sub>max</sub> by 77% and 145%, respectively.</p></div>
<div class="block rep_considerations drugH1Div" id="F53236748"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 1 week after the last alpelisib dose. Patients with partners who could become pregnant should use condoms and effective contraception during therapy and for 1 week after the last dose of alpelisib.</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to the Fulvestrant monograph for additional information.</p></div>
<div class="block pri drugH1Div" id="F53236747"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to alpelisib may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to the fulvestrant monograph for additional information.</p></div>
<div class="block mopp drugH1Div" id="F56767237"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Pregnancy test (prior to treatment in patients who may become pregnant), electrolytes, calcium, phosphorus, CBC, liver function tests (periodically during therapy). Growth in pediatric patients (eg, height, weight) and development. Monitor for diarrhea; signs/symptoms of colitis (eg, abdominal pain, mucus or blood in stool), severe cutaneous adverse reactions, hyperglycemia, hypersensitivity, respiratory symptoms (new or worsening) indicative of pneumonitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia:</p>
<p style="text-indent:-2em;margin-left:4em;">Prior to initiation: Fasting plasma glucose (FPG) and HbA<sub>1c</sub> prior to initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">During therapy: HbA<sub>1c</sub> every 3 months and as clinically indicated. Fasting plasma glucose (FPG) or fasting blood glucose at least once each week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated; monitor fasting more closely in patients with risk factors for hyperglycemia. If hyperglycemia occurs, monitor fasting glucose as clinically indicated, and at least twice weekly until blood glucose or FPG decreases to normal levels. During treatment with antihyperglycemic medication, continue monitoring blood glucose or FPG at least once each week for 8 weeks, followed by once every 2 weeks and as clinically indicated.</p></div>
<div class="block pha drugH1Div" id="F53236755"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib is a small-molecule phosphatidylinositol-3-kinase (PI3K) inhibitor with selective (and strong) activity against PI3Kα (André 2019). Mutations in the gene encoding the catalytic α-subunit of PI3K (PI3KCA) lead to activation of PI3Kα and Akt-signaling, cellular transformation, and tumor generation. Alpelisib inhibits phosphorylation of PI3K downstream targets (including Akt) and demonstrated activity in cell lines harboring a PIK3CA mutation. When compared with either agent alone, the combination of alpelisib with fulvestrant has synergistic antitumor activity in PIK3CA-mutated, estrogen receptor-positive models (André 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Activating mutations in PIK3CA may induce a spectrum of overgrowths/malformations comprising clinically recognizable disorders commonly known as PIK3CA-related overgrowth spectrum (PROS) (Venot 2018). In an animal model PROS phenotype (congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal syndrome [CLOVES]), alpelisib inhibited the PI3K pathway, resulting in prevention or improvement of organ abnormalities associated with the disease; findings were reversed following alpelisib withdrawal.</p></div>
<div class="block phk drugH1Div" id="F53236756"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 114 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 89%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily by chemical and enzymatic hydrolysis to form its metabolite BZG791, and to a lesser extent by CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 8 to 9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Following a single 400 mg dose: Feces: 81% (36% as unchanged drug, 32% as BZG791); Urine: 14% (2% as unchanged drug, 7% as BZG791).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 9.2 L/hour (under fed conditions).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521875"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Pivikto</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Trezilent</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Piqray | Vijoice</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Piqray (200 mg Daily Dose) | Piqray (250 mg Daily Dose) | Piqray (300 mg Daily Dose)</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Piqray</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pimreva</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Pivikto | Trezilent</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31091374">
<a name="31091374"></a>André F, Ciruelos E, Rubovszky G, et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. <i>N Engl J Med</i>. 2019;380(20):1929-1940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpelisib-pediatric-drug-information/abstract-text/31091374/pubmed" id="31091374" target="_blank">31091374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpelisib-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31626273">
<a name="31626273"></a>Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. <i>Ann Oncol</i>. 2019;30(suppl 10):x21-x26. doi: 10.1093/annonc/mdz440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpelisib-pediatric-drug-information/abstract-text/31626273/pubmed" id="31626273" target="_blank">31626273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Piqray.1">
<a name="Piqray.1"></a>Piqray (alpelisib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32416251">
<a name="32416251"></a>Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. <i>Ann Oncol</i>. 2020;31(8):1001-1010. doi:10.1016/j.annonc.2020.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpelisib-pediatric-drug-information/abstract-text/32416251/pubmed" id="32416251" target="_blank">32416251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed May 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29899452">
<a name="29899452"></a>Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. <i>Nature</i>. 2018;558(7711):540-546. doi:10.1038/s41586-018-0217-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alpelisib-pediatric-drug-information/abstract-text/29899452/pubmed" id="29899452" target="_blank">29899452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vijoice.1">
<a name="Vijoice.1"></a>Vijoice (alpelisib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 138443 Version 37.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
